Evidence map›Paper›PMID 40578439›Full record

ArticleAmerican journal of infection control2025

Characterization of patients with Candida (Candidozyma) auris before and during the COVID-19 pandemic in New York, 2017-2022.

Haillie C Meek, Stacey Konkle, Belinda Ostrowsky, Eli S Rosenberg, Karen Southwick, Sarah Kogut, Monica Quinn, Ernest J Clement, Emily Lutterloh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Surveillance for Candida auris - United States, 2022-2024.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haillie C MeekNew York State Department of Health, Albany, NY, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: Haillie.meek@health.ny.gov.
Stacey KonkleNew York State Department of Health, Albany, NY, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Belinda OstrowskyDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Eli S RosenbergNew York State Department of Health, Albany, NY, USA; Department of Epidemiology and Biostatistics, University at Albany College of Integrated Health Sciences, State University of New York, Albany, NY, USA.
Karen SouthwickNew York State Department of Health, Albany, NY, USA.
Sarah KogutNew York State Department of Health, Albany, NY, USA.
Monica QuinnNew York State Department of Health, Albany, NY, USA.
Ernest J ClementNew York State Department of Health, Albany, NY, USA.
Emily LutterlohNew York State Department of Health, Albany, NY, USA; Department of Epidemiology and Biostatistics, University at Albany College of Integrated Health Sciences, State University of New York, Albany, NY, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundCandida auris causes severe, invasive infections. We characterized C. auris epidemiology in New York before and during the coronavirus disease 2019 (COVID-19) pandemic.

methodsMultiple statewide databases were linked to assess demographic and clinical characteristics and outcomes among C. auris screening cases (patients tested for colonization screening) and clinical cases (patients tested to diagnose disease). Cases diagnosed during 2017-2022 were divided into four phases (pre-COVID-19, first wave, ongoing mitigation, and vaccine era ) and compared. Joinpoint analysis was used to assess monthly percentage change (MPC) and temporal trends among clinical cases.

resultsDuring the first wave, higher proportions of C. auris cases were among Black and Hispanic patients (clinical and screening), patients from high social vulnerability index neighborhoods (clinical), and patients aged < 60 years (screening), compared with pre-COVID-19. Increased proportions of Hispanic patients and those aged < 60 years among screening cases persisted through ongoing mitigation and vaccine era. MPC of clinical cases was stable throughout the analysis period (1.97%), and there were no significant joinpoints.

conclusionsCOVID-19 hospitalizations might have driven shifts in characteristics of clinical and screening C. auris cases. Clinical C. auris incidence increased during 2017-2022, but the incidence slope did not increase.

Indexed as

Candida aurisCandidiasisCOVID-19AdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNew YorkPandemicsSARS-CoV-2Young AdultCandida aurisCOVID-19Emerging diseasesInfection controlMultidrug resistance

Identifiers

PMID40578439
PMCPMC13231516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.